HIV-1

HIV-1
Name	Human immunodeficiency virus type 1
Virus group	Retroviridae
Familia	Retroviridae
Genus	Lentivirus

HIV-1 Human immunodeficiency virus type 1 is a lentiviral pathogen responsible for a global pandemic that causes progressive immune deficiency. Discovered in the early 1980s, it has driven major initiatives by World Health Organization, Centers for Disease Control and Prevention, and national public health agencies, and catalyzed breakthroughs recognized by awards such as the Nobel Prize in Physiology or Medicine. Research on its biology intersects work at institutions like National Institutes of Health, Pasteur Institute, and Wellcome Trust–funded centers.

Virology and Structure

HIV-1 is an enveloped, positive-sense single-stranded RNA virus in the family Retroviridae, genus Lentivirus, with structural proteins encoded by genes analogous to those characterized in early studies at the Pasteur Institute and Rockefeller University. The virion contains two copies of genomic RNA packaged with nucleocapsid proteins and reverse transcriptase enzymes, paralleling enzyme studies at Cold Spring Harbor Laboratory and Max Planck Institute laboratories. Surface glycoproteins mediate host entry via interaction with CD4 and chemokine coreceptors, methods elucidated in collaborations that included teams at Harvard Medical School, Johns Hopkins University, and University of Oxford. Viral assembly and budding exploit host pathways identified in research from Massachusetts Institute of Technology and Stanford University, while structural biology efforts using cryo-EM by groups at European Molecular Biology Laboratory and Scripps Research resolved envelope conformations.

Transmission and Epidemiology

Transmission occurs through exposure to infected bodily fluids during activities documented in epidemiological reports by UNAIDS, World Health Organization, and national surveillance programs such as Public Health England and the United States Public Health Service. Major transmission routes include sexual contact, perinatal exposure during childbirth or breastfeeding, and parenteral exposure via shared needles, topics central to policy discussions in forums like the G7 summit and initiatives by Bill & Melinda Gates Foundation. Epidemic patterns vary by region, with concentrated epidemics and generalized epidemics tracked by datasets compiled by Joint United Nations Programme on HIV/AIDS, national ministries of health such as Ministry of Health and Family Welfare (India) and responses coordinated with nongovernmental organizations including Doctors Without Borders and American Red Cross. Historical spread and founder events have been reconstructed using phylogenetics methods developed at University of Cambridge and University of California, Berkeley.

Pathogenesis and Clinical Manifestations

Pathogenesis involves viral entry into CD4+ T lymphocytes, chronic immune activation, and progressive CD4 decline, mechanisms explored in immunology laboratories at Yale University, University of Pennsylvania, and Imperial College London. Opportunistic infections and malignancies emerge as immunodeficiency progresses, clinical patterns extensively described in cohort studies led by Kaiser Permanente, Framingham Heart Study investigators for comorbidity comparisons, and treatment trials coordinated through networks like the International AIDS Society. Common clinical presentations include acute retroviral syndrome, chronic asymptomatic infection, and AIDS-defining illnesses such as Pneumocystis jirovecii pneumonia, Kaposi sarcoma, and Mycobacterium tuberculosis coinfections, issues central to clinical guidelines from National Institute for Health and Care Excellence and U.S. Food and Drug Administration. Long-term complications, including neurocognitive impairment and cardiovascular disease, have been characterized in longitudinal studies at Mount Sinai Health System and Massachusetts General Hospital.

Diagnosis and Laboratory Testing

Diagnosis relies on serologic assays and nucleic acid amplification tests developed and validated by commercial and academic laboratories, with standards set by regulatory bodies such as the World Health Organization, European Medicines Agency, and U.S. Food and Drug Administration. Screening algorithms use antigen/antibody combination immunoassays and confirmatory tests like Western blot historically, with newer protocols incorporating fourth-generation assays and viral load quantification by PCR platforms produced by manufacturers such as Roche Diagnostics and Abbott Laboratories. Resistance testing and genotypic interpretation frameworks were advanced through consortia including the Stanford University HIV Drug Resistance Database and clinical trial networks coordinated by National Institutes of Health.

Treatment and Antiretroviral Therapy

Antiretroviral therapy (ART) employs drug classes including nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, and entry inhibitors—the clinical development of which involved pharmaceutical firms such as Gilead Sciences, GlaxoSmithKline, and Merck & Co. and academic collaborators at University of California, San Francisco and Columbia University. Treatment guidelines from bodies like World Health Organization, Department of Health and Human Services (United States), and European AIDS Clinical Society recommend combination regimens to achieve viral suppression, informed by randomized trials such as those sponsored by the International AIDS Vaccine Initiative and networks like INSIGHT. Drug resistance surveillance and adherence interventions have been implemented via public programs run by entities including Bill & Melinda Gates Foundation and Global Fund to Fight AIDS, Tuberculosis and Malaria.

Prevention and Public Health Measures

Prevention strategies include condom promotion, needle and syringe programs supported by organizations like Harm Reduction International, pre-exposure prophylaxis regimens developed with involvement from Centers for Disease Control and Prevention and World Health Organization, and voluntary medical male circumcision initiatives evaluated by research consortia including UNAIDS. Mother-to-child transmission prevention programs implemented by ministries of health and partnerships with UNICEF have reduced perinatal incidence in many settings, while surveillance, testing campaigns, and stigma-reduction efforts have involved civil society groups such as Amnesty International and Human Rights Watch. Vaccine research and cure efforts continue in trials coordinated by National Institutes of Health, biotech companies, and academic centers like University of Oxford and Fred Hutchinson Cancer Center.

Category:Viruses Category:Retroviruses